{"success":true,"data":{"pressRelease":{"id":"152533","rtpr_id":"nBw8gDxtja-20260924","ticker":"QGEN","exchange":"NYSE","all_tickers":["QGEN","QIA"],"title":"QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation ","author":"Business Wire","published_at":"2026-09-24T20:05:00.272Z","article_body":"QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation\n\n\n * Compact system offers research laboratories a time-saving and cost-efficient\nway to automate work still done by hand\n\n * Reduction in hands-on time of over 80% compared with manual sample processing\n\n * Third new sample preparation system launched in 2026 expands automation\nportfolio from small research labs to high-throughput research and clinical\ntesting\n\nQIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the\nlaunch of QIAmini, a compact automated sample preparation system designed to\ngive research laboratories a time-saving and cost-efficient alternative to\nprocessing samples by hand.\n\nQIAmini is designed primarily for academic laboratories and other research\ncustomers processing smaller sample batches that do not require larger\nautomated systems. QIAGEN estimates the addressable market at more than\n100,000 potential instrument placements worldwide. Automation can reduce\nrepetitive manual work and free up skilled laboratory staff, which can be\ndifficult to recruit and retain.\n\nQIAmini is a benchtop system with a footprint about the size of a sheet of\nprinter paper. It processes up to eight samples per run and automates DNA and\nRNA extraction and purification. Across evaluated workflows, QIAmini reduced\nhands-on time by over 80%.\n\n“Automation should not depend on batch size,” said Nitin Sood, Senior Vice\nPresident and Head of Product Portfolio & Innovation at QIAGEN. “QIAmini\ngives labs processing smaller batches a practical way to replace repetitive\nmanual work with automation. It also expands our automation portfolio from\nsmall batches to high-throughput research and clinical testing.”\n\nFive dedicated QIAmini kits support DNA and RNA sample processing from\nbiological materials such as tissue, cells, cheek swabs, whole blood, body\nfluids and stool. Applications include PCR, digital PCR and next-generation\nsequencing (NGS).\n\nQIAmini is the third new QIAGEN sample preparation system launched in 2026. It\nfollows QIAsprint Connect for high-throughput research sample processing and\nQIAsymphony Connect for medium-throughput sample processing in research and\nclinical laboratories.\n\nFor more information about QIAmini, visit https://www.qiagen.com/qiamini\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.qiagen.com%2Fqiamini&esheet=54610496&newsitemid=20260924784209&lan=en-US&anchor=https%3A%2F%2Fwww.qiagen.com%2Fqiamini&index=1&md5=11136873a1b0416e39020525e468afd9)\nor register for the Qrious Show on October 8 at\nhttps://www.qiagen.com/knowledge-and-support/knowledge-hub/events-and-webinars/qiamini\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.qiagen.com%2Fknowledge-and-support%2Fknowledge-hub%2Fevents-and-webinars%2Fqiamini&esheet=54610496&newsitemid=20260924784209&lan=en-US&anchor=https%3A%2F%2Fwww.qiagen.com%2Fknowledge-and-support%2Fknowledge-hub%2Fevents-and-webinars%2Fqiamini&index=2&md5=222aae22bd2311d2fd6e904cf759b10f)\n\nQIAmini is intended for research use only and not for use in diagnostic\nprocedures.\n\nAbout QIAGEN\n\nQIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample\nto Insight solutions that enable customers to extract and analyze molecular\ninformation from biological samples containing the building blocks of life.\nOur Sample technologies isolate and process DNA, RNA and proteins from blood,\ntissue and other materials. Assay technologies prepare these biomolecules for\nanalysis, while bioinformatics support the interpretation of complex data to\ndeliver actionable insights. Automation solutions integrate these steps into\nstreamlined, cost-effective workflows. QIAGEN serves more than 500,000\ncustomers worldwide in the Life Sciences (academia, pharmaceutical R&D and\nindustrial applications such as forensics) and Molecular Diagnostics (clinical\nhealthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across\nmore than 35 locations. For more information, visit www.qiagen.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.qiagen.com&esheet=54610496&newsitemid=20260924784209&lan=en-US&anchor=www.qiagen.com&index=3&md5=6638b94d9c038e4f5f15af3bde83e6fd)\n.\n\nForward-Looking Statement\n\nCertain statements in this press release may constitute forward-looking\nstatements within the meaning of the U.S. federal securities laws. These\nstatements include, among others, statements regarding QIAGEN’s products,\nproduct development and launches, regulatory approvals, market opportunities\nand future business performance. Forward-looking statements are based on\ncurrent expectations and assumptions and involve risks and uncertainties that\ncould cause actual results to differ materially. These risks include, among\nothers, the development and commercial success of new products, regulatory\napprovals, competition, changes in customer demand and funding, economic and\nmarket conditions, supply chain disruptions, cybersecurity incidents,\nlitigation and other risks described under “Risk Factors” in QIAGEN’s\nmost recent Annual Report on Form 20-F and other filings with the U.S.\nSecurities and Exchange Commission. QIAGEN undertakes no obligation to update\nany forward-looking statement except as required by law.\n\nSource: QIAGEN N.V.\n\nCategory: Life Sciences\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260924784209/en/\n(https://www.businesswire.com/news/home/20260924784209/en/)\n\nQIAGEN contacts:\n\nPublic Relations\n\ne-mail: pr@QIAGEN.com (mailto:pr@QIAGEN.com)\n\nInvestor Relations\n\ne-mail: ir@QIAGEN.com (mailto:ir@QIAGEN.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw8gDxtja-20260924","title":"QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation ","author":"Business Wire","ticker":"QGEN","created":"2026-09-24T20:05:00.272Z","tickers":["QGEN","QIA"],"exchange":"NYSE","article_body":"QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation\n\n\n * Compact system offers research laboratories a time-saving and cost-efficient\nway to automate work still done by hand\n\n * Reduction in hands-on time of over 80% compared with manual sample processing\n\n * Third new sample preparation system launched in 2026 expands automation\nportfolio from small research labs to high-throughput research and clinical\ntesting\n\nQIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the\nlaunch of QIAmini, a compact automated sample preparation system designed to\ngive research laboratories a time-saving and cost-efficient alternative to\nprocessing samples by hand.\n\nQIAmini is designed primarily for academic laboratories and other research\ncustomers processing smaller sample batches that do not require larger\nautomated systems. QIAGEN estimates the addressable market at more than\n100,000 potential instrument placements worldwide. Automation can reduce\nrepetitive manual work and free up skilled laboratory staff, which can be\ndifficult to recruit and retain.\n\nQIAmini is a benchtop system with a footprint about the size of a sheet of\nprinter paper. It processes up to eight samples per run and automates DNA and\nRNA extraction and purification. Across evaluated workflows, QIAmini reduced\nhands-on time by over 80%.\n\n“Automation should not depend on batch size,” said Nitin Sood, Senior Vice\nPresident and Head of Product Portfolio & Innovation at QIAGEN. “QIAmini\ngives labs processing smaller batches a practical way to replace repetitive\nmanual work with automation. It also expands our automation portfolio from\nsmall batches to high-throughput research and clinical testing.”\n\nFive dedicated QIAmini kits support DNA and RNA sample processing from\nbiological materials such as tissue, cells, cheek swabs, whole blood, body\nfluids and stool. Applications include PCR, digital PCR and next-generation\nsequencing (NGS).\n\nQIAmini is the third new QIAGEN sample preparation system launched in 2026. It\nfollows QIAsprint Connect for high-throughput research sample processing and\nQIAsymphony Connect for medium-throughput sample processing in research and\nclinical laboratories.\n\nFor more information about QIAmini, visit https://www.qiagen.com/qiamini\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.qiagen.com%2Fqiamini&esheet=54610496&newsitemid=20260924784209&lan=en-US&anchor=https%3A%2F%2Fwww.qiagen.com%2Fqiamini&index=1&md5=11136873a1b0416e39020525e468afd9)\nor register for the Qrious Show on October 8 at\nhttps://www.qiagen.com/knowledge-and-support/knowledge-hub/events-and-webinars/qiamini\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.qiagen.com%2Fknowledge-and-support%2Fknowledge-hub%2Fevents-and-webinars%2Fqiamini&esheet=54610496&newsitemid=20260924784209&lan=en-US&anchor=https%3A%2F%2Fwww.qiagen.com%2Fknowledge-and-support%2Fknowledge-hub%2Fevents-and-webinars%2Fqiamini&index=2&md5=222aae22bd2311d2fd6e904cf759b10f)\n\nQIAmini is intended for research use only and not for use in diagnostic\nprocedures.\n\nAbout QIAGEN\n\nQIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample\nto Insight solutions that enable customers to extract and analyze molecular\ninformation from biological samples containing the building blocks of life.\nOur Sample technologies isolate and process DNA, RNA and proteins from blood,\ntissue and other materials. Assay technologies prepare these biomolecules for\nanalysis, while bioinformatics support the interpretation of complex data to\ndeliver actionable insights. Automation solutions integrate these steps into\nstreamlined, cost-effective workflows. QIAGEN serves more than 500,000\ncustomers worldwide in the Life Sciences (academia, pharmaceutical R&D and\nindustrial applications such as forensics) and Molecular Diagnostics (clinical\nhealthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across\nmore than 35 locations. For more information, visit www.qiagen.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.qiagen.com&esheet=54610496&newsitemid=20260924784209&lan=en-US&anchor=www.qiagen.com&index=3&md5=6638b94d9c038e4f5f15af3bde83e6fd)\n.\n\nForward-Looking Statement\n\nCertain statements in this press release may constitute forward-looking\nstatements within the meaning of the U.S. federal securities laws. These\nstatements include, among others, statements regarding QIAGEN’s products,\nproduct development and launches, regulatory approvals, market opportunities\nand future business performance. Forward-looking statements are based on\ncurrent expectations and assumptions and involve risks and uncertainties that\ncould cause actual results to differ materially. These risks include, among\nothers, the development and commercial success of new products, regulatory\napprovals, competition, changes in customer demand and funding, economic and\nmarket conditions, supply chain disruptions, cybersecurity incidents,\nlitigation and other risks described under “Risk Factors” in QIAGEN’s\nmost recent Annual Report on Form 20-F and other filings with the U.S.\nSecurities and Exchange Commission. QIAGEN undertakes no obligation to update\nany forward-looking statement except as required by law.\n\nSource: QIAGEN N.V.\n\nCategory: Life Sciences\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260924784209/en/\n(https://www.businesswire.com/news/home/20260924784209/en/)\n\nQIAGEN contacts:\n\nPublic Relations\n\ne-mail: pr@QIAGEN.com (mailto:pr@QIAGEN.com)\n\nInvestor Relations\n\ne-mail: ir@QIAGEN.com (mailto:ir@QIAGEN.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-24T20:05:00.320757708Z","server_sent_at_ms":1790280300320},"received_at":"2026-09-24T20:05:00.394Z","source_url":"https://www.businesswire.com/news/home/20260924784209/en/"},"analysis":{"id":"141337","press_release_id":"152533","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"product_launch","narrative":"QIAGEN launched QIAmini, a compact benchtop system that automates DNA and RNA extraction for research labs processing small sample batches, cutting hands-on time by over 80% versus manual processing.\n\nQIAGEN sizes the addressable market at more than 100,000 potential instrument placements worldwide, and QIAmini is the company's third new sample preparation system launched in 2026.\n\nFive dedicated kits support tissue, blood, swabs and other biological materials for PCR, digital PCR and NGS workflows; the system is research-use only.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Third automation launch of 2026 deepens QIAGEN's small-lab install base funnel."},"keyFigures":{"customDimensions":{"samples_per_run":8,"hands_on_time_reduction":"over 80%","addressable_instrument_placements":"more than 100,000"}},"quotedText":"Automation should not depend on batch size","namedEntities":{"people":[{"name":"Nitin Sood","role":"Senior Vice President and Head of Product Portfolio & Innovation"}],"products":["QIAmini","QIAsprint Connect","QIAsymphony Connect"],"companies":[{"name":"QIAGEN N.V.","ticker":"QGEN","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Routine product launch of a benchtop research-use instrument; expands automation portfolio but no revenue figures or near-term financial impact disclosed."},"tickerRelevance":{"others":[],"primary":"QGEN"},"globalImportance":22,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"routine product launch","sectorWeight":"life sciences tools"}},"event_type":"product_launch","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"QIAGEN launched QIAmini, a compact benchtop system that automates DNA and RNA extraction for research labs processing small sample batches, cutting hands-on time by over 80% versus manual processing.\n\nQIAGEN sizes the addressable market at more than 100,000 potential instrument placements worldwide, and QIAmini is the company's third new sample preparation system launched in 2026.\n\nFive dedicated kits support tissue, blood, swabs and other biological materials for PCR, digital PCR and NGS workflows; the system is research-use only.","key_figures":{"customDimensions":{"samples_per_run":8,"hands_on_time_reduction":"over 80%","addressable_instrument_placements":"more than 100,000"}},"named_entities":{"people":[{"name":"Nitin Sood","role":"Senior Vice President and Head of Product Portfolio & Innovation"}],"products":["QIAmini","QIAsprint Connect","QIAsymphony Connect"],"companies":[{"name":"QIAGEN N.V.","ticker":"QGEN","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-24T20:05:08.008Z","global_importance":22,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap","eventGravity":"routine product launch","sectorWeight":"life sciences tools"}},"durationMs":7604,"modelName":"glm-5.3-flashx"}}